Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
06/1999
06/08/1999US5910489 Treating skin diseases such as cancer, liver spots, genital warts, by topically applying a penetrating formulation of hyaluronic acid and/or salts and an agent to treat the skin such as a nonsteroidal antiinflammatory drug
06/08/1999US5910485 Lower toxicity and high effectiveness through mixture with doxorubicin (adriamycin)
06/08/1999US5910484 Administering hypothalamic inhibitory factor (hif) which has a positive inotropic effect and dilates the coronary arteries to a greater effect than ouabain
06/08/1999US5910478 Peptidomimetics inhibiting the oncogenic action of p21 ras
06/08/1999US5910435 Exposing protein with non-native disulfide bonds to non-protein compound with pka less than 8 and eo greater than -0.25 volts; for proper conformation of heterologous eukaryotic proteins from prokaryotic hosts
06/08/1999US5910431 Polynucleotides encoding chemokine α-2
06/08/1999US5910427 Protein derivatives formed by replacement, substitution, or chemical modification of amino acids 57 and/or 60 having increased activity; for immunosuppressives/allergy treatments
06/08/1999US5910417 Controlling allergic inflammation; by administering to humans a compound which interacts with kinase signal tranduction pathway, suppressing cytokine production
06/08/1999US5910403 Contacting cell with nontoxic stable isotopic label which is incorporated into dna by de novo nucleotide synthesis, detecting amount of label in dna
06/08/1999US5910322 Delayed release pharmaceutical formulation containing amoxycillin and potassium clavulanate
06/08/1999US5910320 Tablet or capsule having a content of stable ranitidine hydrochloride form 1
06/08/1999US5910319 Superior single dose formulation of the antidepressant drug, layer comprising hydroxypropylmethylcellulose acetate succinates
06/08/1999US5910316 Concentrated and localized release of no at a given site in a controllable and predictable manner such that effective dosing can be realized
06/08/1999US5910312 Containing benzoyl peroxide or salicylic acid
06/08/1999US5910311 Inhibiting photoperoxidation of unsaturated lipid by contacting with composition comprising non-photocatalytic metal oxide, tocopherol, metal-inactivating complexing agent
06/08/1999US5910307 Process of extracting and purifying biologically effective ingredients from combined medicinal plants and their extract composition
06/08/1999US5910301 Method of intrapulmonary administration of a narcotic drug
06/08/1999US5909734 Treatment and prevention of bacterial pneumonia; pulmonary aerosolization
06/08/1999CA2255165A1 Benzothiophene derivatives useful in therapy
06/08/1999CA2242308A1 Novel compounds
06/08/1999CA2164179C Dihydroxyacetone, alkylpolyosides and fatty alcohol-containing cosmetic self-tan compositions
06/08/1999CA2136946C Oral decongestant product
06/08/1999CA2089972C Sulfonamidocarboxamides
06/08/1999CA2028465C Novel anthracycline glycoside derivatives and preparing method thereof
06/08/1999CA1340589C Therepeutic nucleosides
06/08/1999CA1340588C Amino acid derivatives
06/04/1999CA2255180A1 N-(4-carbamimido-phenyl)-phenylglycinamid derivatives
06/04/1999CA2253011A1 Dna encoding neospora dihydrofolate reductase-thymidylate synthase
06/04/1999CA2223620A1 Cyclic amp-induced resistance to hiv-1 by downregulation of cc-chemokine receptor 5
06/03/1999WO1999027136A1 Decreasing cell proliferation by decreasing levels of pp5
06/03/1999WO1999027134A1 Antisense oligonucleotide modulation of human serine/threonine protein phosphatase gene expression
06/03/1999WO1999027127A1 NOVEL ribB
06/03/1999WO1999027126A1 ribG
06/03/1999WO1999027125A1 ribA
06/03/1999WO1999027101A1 Method for preparing adenovirus vectors, vectors so prepared, and uses thereof
06/03/1999WO1999027098A2 A-33 related antigens and their pharmacological uses
06/03/1999WO1999026984A1 Low-molecular heparin modification and remedy for skin ulcer
06/03/1999WO1999026983A1 Heparin-like compounds, their preparation and use to prevent arterial thrombosis associated with vascular injury and interventions
06/03/1999WO1999026970A1 NOVEL pth
06/03/1999WO1999026966A2 Nuclear receptor ligands and ligand binding domains
06/03/1999WO1999026962A1 Androgenic steroid compounds and a method of making and using the same
06/03/1999WO1999026959A1 NOVEL recJ
06/03/1999WO1999026958A1 Nucleoside analog compositions and uses thereof
06/03/1999WO1999026956A1 A combinatorial library of moenomycin analogs and methods of producing same
06/03/1999WO1999026954A1 Mitochondrially targeted antioxidants
06/03/1999WO1999026945A1 1,3,4-THIADIAZOLES AND 1,3,4-OXADIAZOLES AS αvβ3 ANTAGONISTS
06/03/1999WO1999026944A1 New compounds which are p2-purinoceptor 7-transmembrane (tm) g-protein coupled receptor antagonists
06/03/1999WO1999026943A1 Thrombin receptor antagonists
06/03/1999WO1999026942A1 5-(2-imidazolinylamino)-benzimidazole derivatives, their preparation and their use as .alpha.-adrenoceptor agonists with improved metabolic stability
06/03/1999WO1999026940A2 Method for producing 8-methoxy-quinoline carboxylic acids
06/03/1999WO1999026939A1 Intermediates and methods useful in the semisynthesis of paclitaxel and analogs
06/03/1999WO1999026929A1 Substituted 11-phenyl-dibenzazepine compounds useful for the treatment or prevention of diseases characterized by abnormal cell proliferation
06/03/1999WO1999026927A2 Metabotropic glutamate receptor antagonists for treating central nervous system diseases
06/03/1999WO1999026926A1 Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors
06/03/1999WO1999026924A1 Substituted oximes as neurokinin antagonists
06/03/1999WO1999026921A1 SUBSTITUTED β-ALANINE DERIVATIVES AS CELL ADHESION INHIBITORS
06/03/1999WO1999026918A1 Biphenylamidine derivatives
06/03/1999WO1999026909A2 Alpha-hydroxy, -amino and -fluoro derivatives of beta-sulphonyl hydroxamic acids as matrix metalloproteinases inhibitors
06/03/1999WO1999026661A1 A covalent conjugate of clozapine with a fatty acid and its use for treating schizophrenia
06/03/1999WO1999026659A1 Combination of an aldose reductase inhibitor and a glycogen phosphorylase inhibitor
06/03/1999WO1999026657A1 Inhibitors of nitric oxide synthase
06/03/1999WO1999026655A1 Method for inhibiting premature rupture of fetal membranes, ripening of uterine cervix and preterm labor
06/03/1999WO1999026651A1 ribH
06/03/1999WO1999026650A1 ribB
06/03/1999WO1999026646A1 ribA
06/03/1999WO1999026645A1 Method of mobilizing hematopoietic stem cells
06/03/1999WO1999026643A1 Methods of preparation of bioginkgo
06/03/1999WO1999026638A1 Reducing blood cholesterol by in vivo precipitation of bile constituents with group ii or -iii metal substances
06/03/1999WO1999026636A1 Pharmaceutical formulation for stimulating the growth of gram-positive bacilli and increasing the acidity in vagina and the use thereof
06/03/1999WO1999026635A1 Pharmaceutical formulation for stimulating the growth of gram-positive bacilli and increasing the acidity in vagina and the use thereof
06/03/1999WO1999026633A1 Citicoline to treat motor neuron diseases and demyelinating diseases
06/03/1999WO1999026632A1 Phospholipids having antimicrobial activity with or without the presence of antimicrobials
06/03/1999WO1999026631A1 Methods for treating postmenopausal women using ultra-low doses of estrogen
06/03/1999WO1999026630A1 Testosterone inhibitors and use for the protection of neurons
06/03/1999WO1999026629A1 Ep2-receptor agonists as neuroprotective agents for the eye
06/03/1999WO1999026628A1 Use of substituted 11-phenyl-dibenzazepine compounds for the treatment or prevention of sickle cell disease, inflammatory diseases characterized by abnormal cell proliferation, diarrhea and scour
06/03/1999WO1999026627A1 (-)-mefloquine to block purinergic receptors and to treat movement or neurodegenerative disorders
06/03/1999WO1999026626A1 Spheroids containing tiagabine, preparation process and pharmaceutical compositions
06/03/1999WO1999026625A1 Formulations comprising dissolved paroxetine
06/03/1999WO1999026624A1 Use of substituted diphenyl indanone, indane and indole compounds for the treatment or prevention of sickle cell disease, inflammatory diseases characterized by abnormal cell proliferation, diarrhe and scours
06/03/1999WO1999026622A1 Use of fc101 as an angiogenesis inhibitor for the treatment of cancer and other angiogenic diseases
06/03/1999WO1999026621A1 Application of substituted aminomethyl chromans in order to prevent neural degeneration and to promote neural regeneration
06/03/1999WO1999026620A1 Choline esters of fatty acids and their use in the treatment of stroke
06/03/1999WO1999026619A1 Skin rash prevention composition
06/03/1999WO1999026618A1 Skin protection composition
06/03/1999WO1999026617A1 Use of a mixture of a diol and an alpha-hydroxy acid for the treatment of hyperkeratotic skin diseases
06/03/1999WO1999026616A1 Benzenesulfonamide inhibitors of pde-iv and their therapeutic use
06/03/1999WO1999026615A1 Cyclic amino acid derivatives as cell adhesion inhibitors
06/03/1999WO1999026614A1 Substituted 2-aminoacetamides and the use thereof
06/03/1999WO1999026613A1 Aminoguanidine compositions for treating skin proliferative diseases
06/03/1999WO1999026612A1 Novel cannabinoid receptor modulators
06/03/1999WO1999026611A1 Substituted diphenyl indanone, indane and indole compounds and analogues thereof useful for the treatment or prevention of diseases characterized by abnormal cell proliferation
06/03/1999WO1999026610A1 Skin care composition
06/03/1999WO1999026609A2 Therapeutic treatment for chronic myeloid leukemia and acute lymphoid leukemia
06/03/1999WO1999026608A1 Spheroids, preparation method and pharmaceutical compositions
06/03/1999WO1999026607A1 Drug delivery systems utilizing crystal structures
06/03/1999WO1999026606A2 SUSTAINED RELEASE FORMULATIONS COMPRISING α-GLUCOSIDASE-INHIBITORS
06/03/1999WO1999026604A2 Selected c10 perfluorinated hydrocarbons for liquid ventilation and artificial blood
06/03/1999WO1999026589A2 Composition for the treatment of burns, sunburns, abrasions, ulcers and cutaneous irritation
06/03/1999WO1999026584A2 Inhibitors of gap junction communication
1 ... 6491 6492 6493 6494 6495 6496 6497 6498 6499 6500 6501 6502 6503 6504 6505 6506 6507 6508 6509 6510 6511 ... 7860